Welcome to the EAS 2023 Interactive Program

How can we reduce cardiovascular risk targeting inflammation via IL-6? - Industry Sponsored Session by Novo Nordisk. Despite control of conventional risk factors, many patients with atherosclerotic cardiovascular disease experience recurrent cardiovascular events. In this symposium chaired by Peter Libby (US), Alberico Catapano (Italy) will review the concept of residual cardiovascular risk and hsCRP as a predictor of cardiovascular risk. Peter Libby will then present the role of inflammation, specifically IL-6, as a driver of residual cardiovascular risk. Finally, Lale Tokgözoğlu (Turkey) will provide an overview of anti-inflammatory therapy for cardiovascular risk reduction. Attendees will have the opportunity to ask questions to the faculty in a live Q&A session at the end of the symposium.